Alexander Monto

Summary

Country: USA

Publications

  1. doi request reprint Lessons from HIV therapy applied to viral hepatitis therapy: summary of a workshop
    Alexander Monto
    Department of Medicine, San Francisco Veterans Affairs Medical Center, San Francisco, California 94121, USA
    Am J Gastroenterol 105:989-1004; quiz 988, 1005. 2010
  2. ncbi request reprint Liver disease in injection drug users with hepatitis C, with and without HIV coinfection
    Alexander Monto
    San Francisco Veterans Affairs Medical Center, CA, USA
    J Addict Dis 27:49-59. 2008
  3. ncbi request reprint Contributions to hepatic fibrosis in HIV-HCV coinfected and HCV monoinfected patients
    Alexander Monto
    Gastroenterology Section, Veterans Affairs Medical Center, San Francisco, California 94121, USA
    Am J Gastroenterol 101:1509-15. 2006
  4. ncbi request reprint Risks of a range of alcohol intake on hepatitis C-related fibrosis
    Alexander Monto
    Department of Gastroenterology, University of California at San Francisco, 4150 Clement Street 111B, San Francisco, CA 94121, USA
    Hepatology 39:826-34. 2004
  5. pmc Monocyte activation in HIV/HCV coinfection correlates with cognitive impairment
    Hans Rempel
    Department of Laboratory Medicine, Veterans Affairs Medical Center, San Francisco, California, USA
    PLoS ONE 8:e55776. 2013
  6. ncbi request reprint Hepatic steatosis in HIV/hepatitis C coinfection: prevalence and significance compared with hepatitis C monoinfection
    Alexander Monto
    Gastroenterology Section, Veterans Affairs Medical Center, University of California, 4150 Clement Street 111B, San Francisco, CA 94121, USA
    Hepatology 42:310-6. 2005
  7. ncbi request reprint Expanded use of aggressive therapies improves survival in early and intermediate hepatocellular carcinoma
    Edith Y Ho
    Division of Gastroenterology, Department of Medicine, University of California San Francisco, San Francisco, CA, USA
    HPB (Oxford) 16:758-67. 2014
  8. pmc Nonresponse to interferon-α based treatment for chronic hepatitis C infection is associated with increased hazard of cirrhosis
    Myrna L Cozen
    Department of Medicine, Veterans Affairs Medical Center and University of California San Francisco, San Francisco, California, USA
    PLoS ONE 8:e61568. 2013
  9. pmc Non-Markov multistate modeling using time-varying covariates, with application to progression of liver fibrosis due to hepatitis C following liver transplant
    Peter Bacchetti
    University of California, San Francisco, CA, USA
    Int J Biostat 6:Article 7. 2010
  10. doi request reprint Retreatment of hepatitis C with consensus interferon and ribavirin after nonresponse or relapse to pegylated interferon and ribavirin: a national VA clinical practice study
    Helen S Yee
    Gastroenterology Section, Department of Veterans Affairs Medical Center VAMC, 4150 Clement Street 111B, San Francisco, CA 94121, USA
    Dig Dis Sci 56:2439-48. 2011

Collaborators

Detail Information

Publications21

  1. doi request reprint Lessons from HIV therapy applied to viral hepatitis therapy: summary of a workshop
    Alexander Monto
    Department of Medicine, San Francisco Veterans Affairs Medical Center, San Francisco, California 94121, USA
    Am J Gastroenterol 105:989-1004; quiz 988, 1005. 2010
    ..This article summarizes that conference...
  2. ncbi request reprint Liver disease in injection drug users with hepatitis C, with and without HIV coinfection
    Alexander Monto
    San Francisco Veterans Affairs Medical Center, CA, USA
    J Addict Dis 27:49-59. 2008
    ..Limiting liver disease progression in IDUs with hepatitis C may well be best accomplished through promoting their full utilization of health care...
  3. ncbi request reprint Contributions to hepatic fibrosis in HIV-HCV coinfected and HCV monoinfected patients
    Alexander Monto
    Gastroenterology Section, Veterans Affairs Medical Center, San Francisco, California 94121, USA
    Am J Gastroenterol 101:1509-15. 2006
    ..The aim of this study was to further explore the severity of liver disease and its predictors in a cohort of hepatitis C virus (HCV) infected patients, some of whom were coinfected with the human immunodeficiency virus (HIV)...
  4. ncbi request reprint Risks of a range of alcohol intake on hepatitis C-related fibrosis
    Alexander Monto
    Department of Gastroenterology, University of California at San Francisco, 4150 Clement Street 111B, San Francisco, CA 94121, USA
    Hepatology 39:826-34. 2004
    ..Age, serum ALT, and inflammation are independently associated with fibrosis in multivariate analysis, highlighting the fact that variables other than alcohol intake predominate in the production of hepatic fibrosis...
  5. pmc Monocyte activation in HIV/HCV coinfection correlates with cognitive impairment
    Hans Rempel
    Department of Laboratory Medicine, Veterans Affairs Medical Center, San Francisco, California, USA
    PLoS ONE 8:e55776. 2013
    ..HIV-suppressed coinfected subjects with controlled HIV viral load experiencing immune activation could benefit significantly from successful anti-HCV therapy and may be considered as preferential candidates...
  6. ncbi request reprint Hepatic steatosis in HIV/hepatitis C coinfection: prevalence and significance compared with hepatitis C monoinfection
    Alexander Monto
    Gastroenterology Section, Veterans Affairs Medical Center, University of California, 4150 Clement Street 111B, San Francisco, CA 94121, USA
    Hepatology 42:310-6. 2005
    ..In conclusion, steatosis is less common in HIV/HCV coinfected patients than similar HCV monoinfected patients, and predictors of steatosis differ between the two groups...
  7. ncbi request reprint Expanded use of aggressive therapies improves survival in early and intermediate hepatocellular carcinoma
    Edith Y Ho
    Division of Gastroenterology, Department of Medicine, University of California San Francisco, San Francisco, CA, USA
    HPB (Oxford) 16:758-67. 2014
    ..Despite the increasing annual incidence of hepatocellular carcinoma (HCC) in the USA, now estimated at 2.7 cases per 100 000 population, only a small proportion of patients receive treatment and 5-year survival rates range from 9% to 17%...
  8. pmc Nonresponse to interferon-α based treatment for chronic hepatitis C infection is associated with increased hazard of cirrhosis
    Myrna L Cozen
    Department of Medicine, Veterans Affairs Medical Center and University of California San Francisco, San Francisco, California, USA
    PLoS ONE 8:e61568. 2013
    ..The long-term consequences of unsuccessful interferon-α based hepatitis C treatment on liver disease progression and survival have not been fully explored...
  9. pmc Non-Markov multistate modeling using time-varying covariates, with application to progression of liver fibrosis due to hepatitis C following liver transplant
    Peter Bacchetti
    University of California, San Francisco, CA, USA
    Int J Biostat 6:Article 7. 2010
    ....
  10. doi request reprint Retreatment of hepatitis C with consensus interferon and ribavirin after nonresponse or relapse to pegylated interferon and ribavirin: a national VA clinical practice study
    Helen S Yee
    Gastroenterology Section, Department of Veterans Affairs Medical Center VAMC, 4150 Clement Street 111B, San Francisco, CA 94121, USA
    Dig Dis Sci 56:2439-48. 2011
    ..As such, CIFN/RBV use and efficacy in clinical practice were evaluated within the Department of Veterans Affairs (VA), the largest national, integrated system for HCV care...
  11. pmc Hepatocellular carcinoma after sustained virologic response in hepatitis C patients without cirrhosis on a pretreatment liver biopsy
    Justin L Sewell
    Gastroenterology Section, University of California San Francisco, San Francisco, California 94143, USA
    Eur J Gastroenterol Hepatol 21:225-9. 2009
    ..As fibrosis may advance, and because SVR and lack of cirrhosis do not fully protect against HCC, future study should further evaluate the risk of HCC among hepatitis C patients after sustained virologic response...
  12. ncbi request reprint A prospective study to examine persistent HCV reinfection in injection drug users who have previously cleared the virus
    Sue L Currie
    Department of Medicine, University of California San Francisco, San Francisco, CA 94121, USA
    Drug Alcohol Depend 93:148-54. 2008
    ..Many HCV-infected persons with recent or ongoing injection drug use (IDU) do not receive HCV treatment due to the perceived risk of HCV reinfection. There are few prospective studies investigating HCV reinfection among IDUs...
  13. pmc The human fetal immune response to hepatitis C virus exposure in utero
    Jennifer M Babik
    Division of Experimental Medicine, Department of Medicine, University of California, San Francisco, CA 94143 1234, USA
    J Infect Dis 203:196-206. 2011
    ..Although the rate of mother-to-child transmission of hepatitis C virus (HCV) is low, the effect of HCV exposure in utero on the fetal immune system is unknown...
  14. doi request reprint Contrast-enhanced CT quantification of the hepatic fractional extracellular space: correlation with diffuse liver disease severity
    Maurice H Zissen
    1 Department of Radiology and Biomedical Imaging, University of California, San Francisco, 505 Parnassus Ave, Box 0628, M 372, San Francisco, CA 94143 0628
    AJR Am J Roentgenol 201:1204-10. 2013
    ..The purpose of this study was to determine whether contrast-enhanced CT quantification of the hepatic fractional extracellular space (ECS) correlates with the severity of diffuse liver disease...
  15. pmc Differential cognitive impairment in HCV coinfected men with controlled HIV compared to HCV monoinfection
    Bing Sun
    Department of Laboratory Medicine, Veterans Affairs Medical Center, San Francisco, CA 94121, USA
    J Acquir Immune Defic Syndr 62:190-6. 2013
    ....
  16. doi request reprint Periprocedural complications by Child-Pugh class in patients undergoing transcatheter arterial embolization or chemoembolization to treat unresectable hepatocellular carcinoma at a VA medical center
    Jeffery S Russell
    Department of Medicine, University of California, San Francisco, Medical Center, USA
    Am J Surg 200:659-64. 2010
    ..The aim of this study was to compare periprocedural complications in a population with hepatitis C virus-related hepatocellular carcinoma to evaluate for differences in complications by severity of liver disease...
  17. pmc Association of hepatitis C virus seropositivity with inflammatory markers and heart failure in persons with coronary heart disease: data from the Heart and Soul study
    Judith I Tsui
    Section of General Internal Medicine, Department of Medicine, Boston University School of Medicine Boston Medical Center, Boston, MA 02118, USA
    J Card Fail 15:451-6. 2009
    ..How hepatitis C virus (HCV) affects coronary heart disease (CHD) risk factors and outcomes is largely unknown...
  18. ncbi request reprint Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol
    Alexander Monto
    Department of Veterans Affairs Medical Center, University of California, San Francisco, San Francisco, CA 94121, USA
    Hepatology 36:729-36. 2002
    ..Significant alcohol or NASH injury was found in only 6% of biopsy specimens. In conclusion, steatosis in HCV infection is associated with risk factors for NASH, particularly obesity, rather than alcohol consumption...
  19. pmc Role of retroviral restriction factors in the interferon-α-mediated suppression of HIV-1 in vivo
    Satish K Pillai
    Department of Medicine, University of California, San Francisco, CA 94143, USA
    Proc Natl Acad Sci U S A 109:3035-40. 2012
    ....
  20. ncbi request reprint Identification of two gene variants associated with risk of advanced fibrosis in patients with chronic hepatitis C
    Hongjin Huang
    Celera Diagnostics, Alameda, California, USA
    Gastroenterology 130:1679-87. 2006
    ..The aim of this study was to identify genetic polymorphisms that can predict the risk of advanced fibrosis in patients with CHC...
  21. ncbi request reprint Fibrosis progression in chronic hepatitis C patients with occult hepatitis B co-infection
    Chee Kin Hui
    Department of Medicine, The University of Hong Kong, Hong Kong SAR, China
    J Clin Virol 35:185-92. 2006
    ..946). In conclusion, chronic HCV patients with occult HBV co-infection does not seem to progress more than patients without occult HBV infection. However, more large-scale studies are needed before a definite conclusion can be obtained...